These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 25295632)

  • 1. [Discovery of a new mutation in MYOD1 characterizes a subset of aggressive embryonal rhabdomyosarcoma partnering with mutations of the PI3K-AKT pathway].
    Orbach D
    Bull Cancer; 2014 Sep; 101(9):776-7. PubMed ID: 25295632
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation.
    Wexler LH; Ladanyi M
    J Clin Oncol; 2010 May; 28(13):2126-8. PubMed ID: 20351321
    [No Abstract]   [Full Text] [Related]  

  • 3. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
    Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
    Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
    Anderson JR; Barr FG; Hawkins DS; Parham DM; Skapek SX; Triche TJ
    J Clin Oncol; 2010 Oct; 28(29):e587-8; author reply e589-90. PubMed ID: 20697086
    [No Abstract]   [Full Text] [Related]  

  • 6. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
    Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
    Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alveolar rhabdomyosarcoma masquerading as embryonal subtype: the value of modern molecular diagnostic testing.
    Eftekhari K; Chambers CB; Goldstein SM; Katowitz WR; Katowitz JA
    Ophthalmic Plast Reconstr Surg; 2015; 31(2):e43-5. PubMed ID: 24608324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A MYOD1 mutation cooperates with PI3K pathway activation in ERMS.
    Cancer Discov; 2014 Jul; 4(7):OF19. PubMed ID: 25002625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embryonal and alveolar rhabdomyosarcoma of parameningeal sites in adults: a report of 13 cases.
    Montone KT; Barr FG; Zhang PJ; Feldman MD; LiVolsi VA
    Int J Surg Pathol; 2009 Feb; 17(1):22-30. PubMed ID: 18945709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features.
    La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C
    Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
    Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
    Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.
    Gallego S; Llort A; Roma J; Sabado C; Gros L; de Toledo JS
    J Cancer Res Clin Oncol; 2006 Jun; 132(6):356-62. PubMed ID: 16435141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pax3 loss of function delays tumour progression in kRAS-induced zebrafish rhabdomyosarcoma models.
    Kahsay A; Rodriguez-Marquez E; López-Pérez A; Hörnblad A; von Hofsten J
    Sci Rep; 2022 Oct; 12(1):17149. PubMed ID: 36229514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma cell lines and a PAX-FOXO1A fusion gene negative alveolar rhabdomyosarcoma cell line.
    Roberts I; Gordon A; Wang R; Pritchard-Jones K; Shipley J; Coleman N
    Cytogenet Cell Genet; 2001; 95(3-4):134-42. PubMed ID: 12063389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility gene card for: Alveolar rhabdomyosarcoma.
    Yu Z; Kelsey A; Alaggio R; Parham D
    Eur J Hum Genet; 2012 Jan; 20(1):. PubMed ID: 21829230
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.
    Wachtel M; Dettling M; Koscielniak E; Stegmaier S; Treuner J; Simon-Klingenstein K; Bühlmann P; Niggli FK; Schäfer BW
    Cancer Res; 2004 Aug; 64(16):5539-45. PubMed ID: 15313887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.